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OBJECTIVES: To calculate the dimension of NSAID induced GI
complications in Europe because few epidemiologic data exist.
To ﬁnd evidence of treatment patterns and analyse data on the
economic burden of NSAID induced GI complications. To assess
the economic beneﬁt of ulcer prophylaxis with proton pump
inhibitors (PPI). METHODS: Pub Med and Cochrane Library
literature research was conducted with deﬁned MESH terms. An
epidemological extrapolation was done to estimate hospitalisa-
tion and death cases due to NSAID use in Europe, limited to
rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Eco-
nomic beneﬁt of ulcer prophylaxis was examined on the basis 
of international cost of illness and cost effectiveness studies.
RESULTS: Eighty-three studies were analysed. Approximately 3
million patients with RA and 17.3 million patients with OA were
calculated for Europe. Potential incidence of hospitalisation due
to NSAID use was 157933 patients annually with estimated
25222 cases of death. In the UK, total costs for inpatient stay
and treatment of complications were about 367.5 million Euros
per year. Data from The Netherlands showed that 14% of the
costs of all GI complications were due to NSAID use. Across
Europe, co-medication studies are rare; in France, co-medication
was prescribed in 29.5%, in Spain in 41.6%, and in The Nether-
lands in 43% of NSAID users. Indirect costs (e.g. loss of pro-
ductivity) ranged from 20–50% of total costs. CONCLUSION:
Compared to our epidemiological extrapolation, much higher
hospitalisation and death rates in Europe must be expected
because of the wide range of NSAID indications. A lack of out-
patient data limits a differentiated calculation of costs for NSAID
induced complications. Although guidelines for ulcer prophy-
laxis do exist in many European countries, daily routine shows
an inconsequent application of gastro protective agents. Given
the calculated prevalences, prophylactic ulcer care with PPI
should receive more attention in Europe.
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OBJECTIVES: Acute-on-chronic liver failure (ACLF) is a life
threatening acute decompensation of a pre-existing chronic liver
disease. The artiﬁcial liver support system MARS is a new emerg-
ing therapeutic option for treatment of ACLF. The medical efﬁ-
cacy of MARS has been demonstrated in ﬁrst clinical studies.
Objective of this study was to determine survival rates, quality
of life, direct medical costs and cost-effectiveness. METHODS:
In a clinical cohort trial with a prospective follow-up of 3 years
and modelling of cost and survival for the remaining lifetime 62
consecutively included ACLF-patients treated with MARS were
compared to 87 controls. Survival, health-related quality of life
as well as direct medical costs for in- and outpatient treatment
from a health care system perspective were determined and by
bootstrapping the incremental costs per life year respectively
QALY gained were estimated. RESULTS: There were no signif-
icant baseline differences between the two groups. Patients
treated with MARS had a highly signiﬁcant better survival
(Logrank) with a mean outcome gain of 0.66 years, but boot-
strap analysis showed broad conﬁdence intervals (−0.12 to 1.46).
The average initial intervention costs for MARS were €14,600
per patient treated. Incremental direct medical costs were
€19,946 per patient treated with MARS (CI: 13,308 to 25,429).
The mean costs per life-year gained were €29,985, costs per
QALY were €43,040. In total, 34% of the bootstrap sample were
higher than €50,000 per QALY. CONCLUSIONS: The results of
the ﬁrst economic evaluation study of MARS based on empiri-
cal patient data are presented. Although high initial treatment
costs for MARS occur the signiﬁcantly better survival led to rea-
sonable costs per live year respectively QALY gained. But boot-
strap analysis of CER showed a probability of 34% to be higher
than 50,000€ per QALY gained. Further randomized controlled
trials investigating the medical efﬁcacy and the cost-effectiveness
are recommended.
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OBJECTIVES: Pariet (rabeprazole) was introduced at a sub-
stantial price discount to existing, branded proton pump
inhibitors (PPIs) in Canada. Therefore, there may have been a
perception of comparative reduced efﬁcacy with Pariet, in part
because Pariet is generally dosed at two tablets daily, compared
to one unit daily for other PPIs. The objective was to conduct
individual claims data descriptive analyses to identify differences
in patterns of use indicative of reduced efﬁcacy or selection of
patients. METHODS: Individual claims data were obtained for
Ontario, Canada. PPI claims were followed backward in time to
determine if the patient had received a different PPI, an H2
antagonist or neither therapy previously (minimum time period,
twelve months). This could suggest selection bias for naïve
patients versus treatment-experienced patients. PPI claims were
followed forward in time to determine if there were subsequent
claims for a different PPI, an H2 antagonist, or neither. This
proxy measure was interpreted as a lack of efﬁcacy requiring
therapy switches. RESULTS: Pariet users were equally likely as
other PPI users to have had no claims for another PPI or H2 in
the previous twelve months (74% PPI market overall, 70%
Pariet). The proporton of patients who subsequently switched
therapy increased as the duration of follow-up increased.
Overall, Pariet users were most likely to have no subsequent
claims for another PPI or an H2 antagonist compared to other
PPIs (59% overall market, 71% Pariet users). CONCLUSION:
Claims data do not support that Pariet has different efﬁcacy from
other PPIs or is used differently.
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HEALTH-STATE UTILITIES IN LIVER DISEASE: A SYSTEMATIC
REVIEW AND META-ANALYSIS
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OBJECTIVES: Health-state utilities are essential for cost-effec-
tiveness analysis, and few estimates exist for liver disease in the
literature. Our aim was to conduct a systematic review of health-
state utilities in liver disease, and to estimate utilities for various
liver disease states for a large UK Department of Health study.
METHODS: Articles were included in the systematic review if
health-state utility tools were used to estimate utility or if they
